Kaleido Biosciences and the COPD Foundation Announce a Strategic Collaboration to Advance KB109 into Phase 2 Clinical Trial

NEXT STORY
Black Diamond Therapeutics Announces Appointment of Mark Velleca, M.D., Ph.D. to Board of Directors
PREV STORY
Direct-to-Patient Market Report 2021-2031
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Glepaglutide meets primary endpoint in Phase 2 trial in patients with short bowel syndrome

Glepaglutide* is a novel long-acting GLP-2 analogue Reduction in fecal wet weight output of ...

author_avatar
NASDAQ Market News

Chi-Med Reports 2020 Interim Results and Provides Updates on Key Clinical Programs

author_avatar
NASDAQ Market News

Athenex Announces Klisyri® (tirbanibulin) Receives Positive CHMP Opinion from the European Medicines Agency (EMA) for the Treatment of Actinic Keratosis of the Face or Scalp

author_avatar
NASDAQ Market News